Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited’s Unit I & III, oral and derma manufacturing facilities located at Jadcherla, Mahabub Nagar District, Telangana, which were inspected by the United States Food and Drug Administration from January 9 to January 18, 2023, have now been classified as Voluntary Action Indicated (VAI), the company said via an exchange filing.
The disclosure is pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
(To receive our E-paper on WhatsApp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)
